-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $20

Benzinga·09/30/2026 18:38:02
Citigroup analyst Joanne Wuensch maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and lowers the price target from $24 to $20.